108 related articles for article (PubMed ID: 21757882)
1. Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker.
Lee HY; Pelivani N; Beltraminelli H; Hegyi I; Yawalkar N; Borradori L
Dermatology; 2011; 222(4):304-10. PubMed ID: 21757882
[TBL] [Abstract][Full Text] [Related]
2. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
3. [Amicrobial pustulosis of the skin folds and autoimmune erythroblastopenia].
Saint-Jean M; Gagey-Caron V; Jossic F; Barbarot S; Hamidou M; Stalder JF
Ann Dermatol Venereol; 2011 May; 138(5):399-404. PubMed ID: 21570565
[TBL] [Abstract][Full Text] [Related]
4. A case of amicrobial pustulosis of the folds associated with neutrophilic gastrointestinal involvement in systemic lupus erythematosus.
Kerl K; Masouyé I; Lesavre P; Saurat JH; Borradori L
Dermatology; 2005; 211(4):356-9. PubMed ID: 16286747
[TBL] [Abstract][Full Text] [Related]
5. Amicrobial pustulosis of the folds associated with Hashimoto's thyroiditis.
López-Navarro N; Alcaide A; Gallego E; Herrera-Acosta E; Gallardo M; Bosch RJ; Herrera E
Clin Exp Dermatol; 2009 Dec; 34(8):e561-3. PubMed ID: 19549241
[TBL] [Abstract][Full Text] [Related]
6. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
[TBL] [Abstract][Full Text] [Related]
8. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
9. Amicrobial pustulosis of the folds: Where have we gone 25years after its original description?
Schissler C; Velter C; Lipsker D
Ann Dermatol Venereol; 2017 Mar; 144(3):169-175. PubMed ID: 28242094
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
11. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
[TBL] [Abstract][Full Text] [Related]
13. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
Joosten AA; van Olffen GH; Hageman G
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
[TBL] [Abstract][Full Text] [Related]
14. [A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease].
Guyot A; Begon E; Abramowitz L; Landry J; Marinho E; Descamps V; Crickx B
Ann Dermatol Venereol; 2009 Nov; 136(11):806-10. PubMed ID: 19917434
[TBL] [Abstract][Full Text] [Related]
15. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
[TBL] [Abstract][Full Text] [Related]
17. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
18. [Psoriasis induced by infliximab].
Fernandes IC; Torres T; Sanches M; Velho G; Lago P; Selores M
Acta Med Port; 2011 Dec; 24 Suppl 3():709-12. PubMed ID: 22856418
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
20. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
